Fri, Jul 25, 2014, 2:35 PM EDT - U.S. Markets close in 1 hr 25 mins

Recent

% | $
Click the to save as a favorite.

Astex Pharmaceuticals, Inc. Message Board

surfer_bj 30 posts  |  Last Activity: Jul 10, 2014 4:46 AM Member since: Sep 28, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Just imagine all the new drugs to hit the markets in the coming quarters/years. Some Blockbuster drugs are in the making and Shorts know that the undervalued stock price has nowhere but up to move....

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 9, 2014 2:10 PM Flag

    I get my numbers from E-Trade account under Fundamentals. E-trade has KEY STATISTICS

    Business Summary
    Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing
    and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary,
    Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize
    BELVIQ in the United States. The Company’s oral drug candidates include APD811, an
    agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension,
    which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the
    treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I
    trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases,
    and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in
    preclinical development. In June 2012, the United States Food and Drug Administration approved
    its internally discovered drug, BELVIQ.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 9, 2014 1:13 PM Flag

    ARNA is being attacked by Wall Street shorts. It's only obvious when you see all the new Usernames flying everywhere in order to create doubt and deceive investors. It's called corruption lead by a number of Wall Street hoods and there followers.

    ARNA has positive growth....and a whole lot of cash. I see many other companies management selling large lots of their shares big time. No big deal is made about their sells that happen with some companies monthly and quarterly.

    I expect very positive future news will come and shorts are scared they would have been stuck even further as sales ramp up and several possible new territories are added to ARNA sales. Growth is better each and every quarter and you and I know it!

    Sentiment: Strong Buy

  • Growth Rate (TTM) Earnings Per Share 67.1 ARNA's EPS Growth Rate is greater than 81% of its peers in the Biotechnology & Drugs industry.

    ARNA's Gross Margin is more than 92% of other companies in the Biotechnology & Drugs industry, which means it has more cash to spend on business operations as compared to its peers. As indicated by the Operating Margin, ARNA controls its costs and expenses better than 65% of its peers.

    Sentiment: Strong Buy

  • July 1 at $5.85 per share. The transaction was an "automatic sell" apparently triggered by a declining share price.

    Sentiment: Strong Buy

  • he knows shorts are trying to find any kind of news to turn the news negative. With AF'S articles he can draw more attention for his own personal agenda. AF is addicted to attention for personal gain and can care less who he hurts on the way.

    I am sure Jack has a good personal reason to sell his shares at this time. Especially when the stock price was lower. One would think the opposite of AF, and think Jack L would have sold more shares at a higher price.

    What would the shorts and AF said if Jack sold his shares at $7.00 or higher? Yes you got it, the Same Ole Negative Remarks they posted today!

    Nothing but manipulation of the stock price for persona gain!...Call the SEC police!

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 3, 2014 5:32 PM Flag

    Add These trials/Studies to Spectrum's future income: Here is a list of Spectrum's Open Studies/trials along with new studies/trials not yet recruiting.| spectrum pharmaceuticals. This is very impressive when looking into Spectrum's future new drugs and earnings potential. List on Spectrum’s website

    Acute Lymphoblastic Leukemia 2 studies
    B-cell Lymphomas 2 studies
    Biliary Tract Cancer 1 study
    Biliary Tract Diseases 1 study
    Biliary Tract Neoplasms 1 study
    Brain Diseases 1 study
    Brain Neoplasms 1 study
    Bronchial Neoplasms 1 study
    Carcinoma 1 study
    Carcinoma, Bronchogenic 1 study
    Carcinoma, Non-Small-Cell Lung 1 study
    Central Nervous System Diseases 1 study
    Central Nervous System Neoplasms 1 study
    Chronic Lymphocytic Leukemia 1 study
    Digestive System Diseases 2 studies
    Digestive System Neoplasms 1 study
    Follicular Lymphoma 1 study
    Gastroenteritis 1 study
    Gastrointestinal Diseases 2 studies
    Gastrointestinal Neoplasms 1 study
    Immunoproliferative Disorders 8 studies
    Leukemia 3 studies
    Leukemia, Lymphocytic, Chronic, B-Cell 1 study
    Leukemia, Lymphoid 3 studies
    Lung Diseases 1 study
    Lung Neoplasms 1 study
    Lymphatic Diseases 8 studies
    Lymphoblastic Lymphoma 1 study
    Lymphoma 8 studies
    Lymphoma, B-Cell 2 studies
    Lymphoma, Follicular 1 study
    Lymphoma, Large B-Cell, Diffuse 2 studies
    Lymphoma, Non-Hodgkin 5 studies
    Lymphoma, Small Cleaved-cell, Diffuse 2 studies
    Lymphoma, T-Cell 3 studies
    Lymphoma, T-Cell, Peripheral 3 studies
    Lymphoproliferative Disorders 8 studies
    Mouth Diseases 1 study
    Mucositis 1 study
    Neoplasm Metastasis 1 study
    Neoplasms, Second Primary 1 study
    Neoplastic Processes 1 study
    Nervous System Neoplasms 1 study
    Peripheral T-cell Lymphoma 3 studies
    Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 studies
    Respiratory Tract Diseases 1 study
    Respiratory Tract Neoplasms 1 study
    Stomatognathic Diseases 1 study
    Thoracic Neoplasms 1 study

    Sentiment: Strong Buy

  • Reply to

    Scheduled Run-Up May be Happening

    by antwan_rockamoora Jun 20, 2014 9:58 PM
    surfer_bj surfer_bj Jul 1, 2014 1:32 PM Flag

    NASDAQ UP 4,470.03 +61.854 (+1.40%) Dow UP 16,995.30 +168.70 (+1.00%) and
    ****PPHM up1.94 +0.060 (+3.19%) ****

    Sentiment: Strong Buy

  • HALO commercial launch of MabThera SC in Europe has triggered a $5 mln milestone payment during the second quarter under the License and Collaboration Agreement between HALO and Roche. Following the launch of Herceptin SC in Sept. 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using HALO's patented Enhanze (recombinant human hyaluronidase) technology to be launched in Europe.

    The approval of MabThera SC in Europe in March 2014 for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma was primarily based on a clinical development program which showed that SC administration enabled the delivery of MabThera over approximately five minutes versus 2.5 hours intravenously without compromising its proven efficacy and safety.

    Sentiment: Strong Buy

  • Reply to

    Filed on 6/23/14

    by wallstreetwolfie Jun 25, 2014 6:25 AM
    surfer_bj surfer_bj Jun 26, 2014 5:30 AM Flag

    PPHM'S has real huge blockbuster drugs in their pipeline. Bavituximab! Financial Impacts of CSM's Errors
    17. As explained below, the ensuing damage to Peregrine is many times the amount paid to CSM for its services, and CSM's errors could not have been more inopportune. With the anticipated success of this trial, Peregrine expected to promptly partner with or be acquired by a global pharmaceutical company and move into a Phase III trial for NSCLC patients and commence other trials. Bavituximab could be potentially developed for or as a cancer vaccine. Bavituximab also has indications of benefit for other diseases such as Hepatitis C and HTV.

    The Phase II study at issue cost in excess of $12,000,000 in direct third party costs alone, not to mention the significant internal man-hours and associated costs. The results of the 3 mg/kg arm of the study have value in that Peregrine was able to combine the "A" and "B" arm results and compare them to the "C" arm results. (The "A" and "B" groups collectively can be assumed to have received some bavituximab at the 1 mg/kg level, and Peregrine can compare their survival data to that of the 3 mg/kg patients.)
    19. Had the study, which was initially reported as demonstrating statistically meaningful overall survival benefits, been confirmed, Peregrine could potentially have sought early approval and sales of the product. This likely would have shaved at least 3 to 4 years from the program and resulted in early commercial sales. While a confirmatory Phase III trial would still need to be done, the FDA's practices and guidances indicate that it would have required only 300-400 patients in our ensuing Phase HI study based on the hazard ratio determined in the Phase II study.
    20. However, once the regulatory violations were confirmed (as discussed in the Masten Declaration), the value of the Phase II study as a registration study was so severely compromised that any option for an early FDA approval was eliminated.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jun 24, 2014 3:27 PM Flag

    . Over the years, the doses of EE most commonly included in CHCs have steadily decreased to 35 micrograms per day or below, due to associated safety risks of higher EE doses. The only currently marketed transdermal patch delivers a dose of EE that is 60% higher than that delivered with low-dose oral contraceptives containing 35 micrograms of EE. As a result, the currently marketed patch carries a black box warning describing safety risks associated with this higher level of EE. Before these issues were identified with the currently marketed patch, it achieved rapid market uptake and quickly captured approximately 10% of the CHC market. We believe there is an unmet market need for a low-dose transdermal patch as a contraceptive option that does not carry the additional safety risks associated with higher levels of EE.

    dose oral contraceptives. The dose of EE in Twirla is much lower than the levels of EE delivered by the currently marketed patch, as reported in that patch's label. Twirla is round and made of a soft, flexible, silky fabric, designed to flex with the movement of a woman's body. Twirla is a matrix patch consisting of several layers of material which contain the active ingredients EE and LNG, inactive ingredients to assist in transport of EE and LNG across the skin, and adhesives that allow adherence to the skin. There is a barrier formed between the inner portion of the patch, which contains the active ingredients, and the outer portion of the patch, which only contains the adhesive. This barrier is intended to prevent the active and inactive ingredients from migrating to the peripheral portion of the patch, and from breaking down the adhesive in that portion of the patch. Twirla is also designed to help prevent seepage of the adhesives from around the edges of the patch where it could collect dirt and leave a sticky black ring on the skin. The six layers of the patch are integrated to create a patch which has a slim profile, less than one half millimeter, and is unobtrusive when applied. The results of multiple clinical trials suggest that Twirla delivers the active ingredients needed for contraception over a seven-day period, and that it remains adhered to the skin of most subjects for the full seven-day period, even under conditions of heat, humidity, showering, exposure to water and vigorous exercise.

    Sentiment: Strong Buy

  • Reply to

    Float locked up ?

    by kellysummers32 Jun 23, 2014 9:59 PM
    surfer_bj surfer_bj Jun 24, 2014 2:53 PM Flag

    Quite period over soon in July...We could hear more news....Collected a lot of cash for the IPO offer. If they should have any new stock offering in could be at $18 or higher....Better yet, with phase III in later stage, a partner could be coming aboard.

    In addition to Twirla, we are developing a pipeline of other new transdermal contraceptive products, including AG200-ER which is a regimen designed to allow a woman to extend the length of her cycle and AG200-SP which is a regimen that will provide a shortened hormone-free interval. We are also developing AG890, which is a P-only prescription contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

    The Company focused on the development and commercialization of new prescription contraceptive products. The Company's product candidates are designed to provide women with contraceptive options that offer convenience and facilitate compliance. The Company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch in Phase III clinical development. Twirla is based on its transdermal patch technology, called Skinfusion, which is designed to provide advantages over available patches and is intended to optimize patch adherence and stability and patient comfort. Twirla is a combined hormonal contraceptive (CHC), patch that contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen, and levonorgestrel (LNG), which is a type of progestin, a synthetic steroid hormone

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jun 23, 2014 2:29 PM Flag

    The United States hormonal contraceptive market, with total market sales of $5.6 billion in 2013, represents the greatest opportunity for Twirla.

    Sentiment: Strong Buy

  • Type UBS UPGRADES HALOZYME THERAPEUTICS, INC. TO BUY
    | S&P Capital IQ
    SNPMarketScopeViewsNews 2014-06-11 16:29:55.000 HALOHALOZYME THERAPEUTICS, INC.Acquire Media UBS UPGRADES HALOZYME THERAPEUTICS, INC. TO BUY UBS upgrades Halozyme Therapeutics, Inc. (NASDAQ: HALO) from Neutral to Buy.

    Sentiment: Strong Buy

  • Reply to

    Todays June 21 $7.00 Option Calls at 8,841 Volume

    by surfer_bj May 20, 2014 1:00 PM
    surfer_bj surfer_bj May 20, 2014 1:10 PM Flag

    This week we have news a "strong" buyout between partners could be in happening. These large volume option calls came as fast as todays news.... Must be related.....

    Sentiment: Strong Buy

  • Wow!! Big bets that Arena soon to be over $7.00. Add that to previous total of 4819 + 8841=13660 total
    June 21, 2014 calls as of today May 20. Look out shorts...

    Sentiment: Strong Buy

  • A Merger using Stock or Stock and Cash. You can never say never that Arena will not be a takeover by Eisai. "Where there's a will there is a way" it can happen! It's only a matter of agreement with the right deal to make it a win, win Merger.

    I am sure, there is news and future plans that Arena/Eisai has kept undercover.

    No writer who pop's out with negative remarks as fast as AF can when there is a positive report about Arena, is considered to be believable. Remember the movie "Big Fat Liar" That is where AF fits in......

    Sentiment: Strong Buy

  • surfer_bj surfer_bj May 15, 2014 11:58 AM Flag

    PTX is now a game changer for shorts....and very positive for a long investment. Love it to see all the scared shorts posting their imaginary plans for PTX.

    PTX . New CEO Doug Drysdale wasted no time has now become very aggressive in transmitting PTX into a multi drug company and adding new surprises very quickly. He has his connections and it sure has nothing to do with anyone not supporting PTX'S growth.

    Shorting PTX with CEO Doug Drysdale in charge...could be a very negative experience.

    Sentiment: Strong Buy

  • New CEO Doug Drysdale wasted no time making a bold move to accelerate the resurrection of PTX as a specialty CNS play, announcing the purchase of the anti-migraine therapy Treximet from GSK. Firm believes the deal is a game changer for PTX as 1) it should substantially elevate short-term profitability; 2) it provides an anchor asset in the CNS space; and 3) it should afford potentially significant out-year upside if PTX can execute life-cycle extension strategies.

    Sentiment: Strong Buy

  • Pipeline Updates: We remind investors that in Apr 2014, the U.S. Food and Drug Administration (FDA) had placed a clinical hold on patient enrollment and dosing of PEGPH20 in a phase II study (Study 202) evaluating PEGPH20 as a first-line therapy for patients suffering from stage IV metastatic pancreatic cancer. However, in May 2014, after reviewing the data provided by Halozyme, the Data Monitoring Committee (DMC) decided that the study may proceed, with modifications, to continue patient enrollment and dosing of PEGPH20.

    Halozyme has provided this information to the FDA requesting the agency to withdraw the clinical hold on Study 202. The company can resume patient enrolment once the clinical hold is lifted.

    Halozyme also has a number of partnered programs. Roche’s (RHHBY - Analyst Report) MabThera SC (subcutaneous formulation of MabThera), developed using Halozyme’s rHuPH20, was approved by the European Commission (EC) in Mar 2014 for the treatment of common forms of non-Hodgkin's lymphoma (NHL), which includes follicular lymphoma and diffuse large B cell lymphoma.

    This new subcutaneous formulation of MabThera can be administered within 5 minutes (compared to 2.5 hours for the intravenous formulation). Roche intends to launch MabThera SC in the EU over the next several months.

    Meanwhile, Hylenex recombinant met the primary endpoint in the CONSISTENT 1 study. Hylenex recombinant and a new formulation of Hylenex are under FDA review as pre-treatment of the insulin infusion site in type I diabetes patients dependent on continuous subcutaneous insulin infusion (CSII).

    Halozyme also announced positive top-line results from a proof of concept phase I/II study on HTI-501 for the treatment of cellulite.

    Additionally, Halozyme is in discussions with the FDA regarding a label update for Hylenex to include important safety and efficacy data.

    Sentiment: Strong Buy

ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.